Kiyomi Mashima, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
WT1 Proteins | 2 | 2018 | 178 | 1.230 |
Why?
|
Antilymphocyte Serum | 2 | 2021 | 491 | 1.190 |
Why?
|
Graft vs Host Disease | 7 | 2024 | 2951 | 1.050 |
Why?
|
Bone Marrow Cells | 2 | 2018 | 2513 | 0.750 |
Why?
|
Myelodysplastic Syndromes | 2 | 2018 | 1351 | 0.650 |
Why?
|
Blast Crisis | 1 | 2018 | 103 | 0.640 |
Why?
|
Lymphoma, Follicular | 5 | 2020 | 435 | 0.590 |
Why?
|
Receptors, Interleukin-2 | 4 | 2019 | 573 | 0.560 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2236 | 0.560 |
Why?
|
Hematopoietic Stem Cell Transplantation | 9 | 2021 | 5425 | 0.550 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 226 | 0.510 |
Why?
|
Leukemia, Myeloid, Acute | 7 | 2019 | 3497 | 0.500 |
Why?
|
Lymphoproliferative Disorders | 1 | 2017 | 525 | 0.450 |
Why?
|
Encephalitis | 1 | 2017 | 423 | 0.450 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 1040 | 0.400 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1835 | 0.400 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2017 | 569 | 0.380 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 11472 | 0.340 |
Why?
|
Bone Marrow | 2 | 2018 | 2941 | 0.330 |
Why?
|
Cytarabine | 6 | 2019 | 684 | 0.310 |
Why?
|
Lymphoma | 4 | 2022 | 1873 | 0.300 |
Why?
|
Tumor Burden | 2 | 2021 | 1905 | 0.260 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 232 | 0.260 |
Why?
|
Gene Expression | 1 | 2018 | 7790 | 0.260 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 689 | 0.230 |
Why?
|
Mice, SCID | 4 | 2024 | 2715 | 0.230 |
Why?
|
Hematologic Neoplasms | 3 | 2019 | 1820 | 0.220 |
Why?
|
Mice, Inbred NOD | 3 | 2024 | 1875 | 0.210 |
Why?
|
Oxidative Phosphorylation | 1 | 2024 | 480 | 0.200 |
Why?
|
Disseminated Intravascular Coagulation | 2 | 2019 | 188 | 0.200 |
Why?
|
Transplantation Conditioning | 2 | 2019 | 1597 | 0.190 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8621 | 0.190 |
Why?
|
T-Lymphocytes | 5 | 2024 | 10163 | 0.190 |
Why?
|
Antiemetics | 1 | 2022 | 176 | 0.190 |
Why?
|
Dermatan Sulfate | 1 | 2019 | 35 | 0.180 |
Why?
|
Multiple Myeloma | 3 | 2023 | 5169 | 0.170 |
Why?
|
Gabexate | 1 | 2018 | 12 | 0.170 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 1377 | 0.170 |
Why?
|
Chondroitin Sulfates | 1 | 2019 | 184 | 0.170 |
Why?
|
Prednisolone | 1 | 2020 | 333 | 0.170 |
Why?
|
Dexamethasone | 3 | 2023 | 1949 | 0.170 |
Why?
|
Busulfan | 1 | 2019 | 262 | 0.170 |
Why?
|
Penicillin G | 1 | 2018 | 42 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1596 | 0.170 |
Why?
|
Myeloablative Agonists | 1 | 2019 | 218 | 0.160 |
Why?
|
Salvage Therapy | 3 | 2019 | 1269 | 0.160 |
Why?
|
Mediastinal Diseases | 1 | 2019 | 89 | 0.160 |
Why?
|
Heparitin Sulfate | 1 | 2019 | 225 | 0.160 |
Why?
|
Cerebral Arteries | 1 | 2021 | 492 | 0.160 |
Why?
|
ROC Curve | 4 | 2019 | 3528 | 0.160 |
Why?
|
Guanidines | 1 | 2018 | 191 | 0.160 |
Why?
|
Disease-Free Survival | 5 | 2020 | 6891 | 0.160 |
Why?
|
Collagen Type I | 1 | 2021 | 592 | 0.150 |
Why?
|
beta-Glucans | 1 | 2018 | 123 | 0.150 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2017 | 647 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 250 | 0.140 |
Why?
|
Retrospective Studies | 19 | 2022 | 77098 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 636 | 0.140 |
Why?
|
Middle Aged | 25 | 2021 | 213127 | 0.140 |
Why?
|
Leukocyte Count | 2 | 2017 | 1583 | 0.140 |
Why?
|
Neoplasm Proteins | 2 | 2019 | 3691 | 0.140 |
Why?
|
Prognosis | 8 | 2021 | 29010 | 0.130 |
Why?
|
Immunity | 1 | 2022 | 1011 | 0.130 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2017 | 433 | 0.130 |
Why?
|
Protease Inhibitors | 1 | 2019 | 790 | 0.130 |
Why?
|
Hyperplasia | 1 | 2018 | 1183 | 0.130 |
Why?
|
Chemokines | 1 | 2019 | 954 | 0.130 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2017 | 659 | 0.130 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2016 | 272 | 0.120 |
Why?
|
Adult | 20 | 2021 | 213712 | 0.120 |
Why?
|
Antigen-Presenting Cells | 1 | 2018 | 969 | 0.120 |
Why?
|
Lymphocyte Activation | 3 | 2020 | 5519 | 0.120 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2077 | 0.120 |
Why?
|
Osteomyelitis | 1 | 2018 | 402 | 0.120 |
Why?
|
Aged | 19 | 2021 | 162944 | 0.120 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 407 | 0.120 |
Why?
|
Neutropenia | 1 | 2019 | 891 | 0.120 |
Why?
|
Pneumococcal Infections | 1 | 2018 | 496 | 0.120 |
Why?
|
Cisplatin | 1 | 2019 | 1637 | 0.110 |
Why?
|
Humans | 40 | 2024 | 742088 | 0.110 |
Why?
|
RNA, Messenger | 2 | 2018 | 13029 | 0.110 |
Why?
|
Transplantation, Homologous | 2 | 2018 | 4771 | 0.110 |
Why?
|
Female | 25 | 2021 | 379592 | 0.110 |
Why?
|
Aniline Compounds | 1 | 2017 | 983 | 0.110 |
Why?
|
Streptococcus pneumoniae | 1 | 2018 | 712 | 0.110 |
Why?
|
Quinolines | 1 | 2017 | 719 | 0.110 |
Why?
|
Nitriles | 1 | 2017 | 952 | 0.110 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1179 | 0.110 |
Why?
|
Antigen Presentation | 1 | 2018 | 1284 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 987 | 0.100 |
Why?
|
Recurrence | 3 | 2019 | 8333 | 0.100 |
Why?
|
Translocation, Genetic | 1 | 2017 | 1417 | 0.100 |
Why?
|
Remission Induction | 4 | 2020 | 2384 | 0.100 |
Why?
|
Blood Transfusion | 1 | 2018 | 1296 | 0.100 |
Why?
|
Male | 26 | 2021 | 349538 | 0.100 |
Why?
|
Myeloproliferative Disorders | 1 | 2018 | 603 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1413 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1837 | 0.100 |
Why?
|
Myeloid Cells | 1 | 2015 | 804 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 1434 | 0.090 |
Why?
|
Autoantibodies | 1 | 2019 | 2036 | 0.090 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2018 | 1581 | 0.090 |
Why?
|
Transplantation, Autologous | 3 | 2021 | 2123 | 0.090 |
Why?
|
Mesenchymal Stem Cells | 1 | 2020 | 1625 | 0.090 |
Why?
|
Aged, 80 and over | 7 | 2019 | 57683 | 0.090 |
Why?
|
Blood Platelets | 1 | 2020 | 2506 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13655 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1052 | 0.080 |
Why?
|
Overweight | 1 | 2019 | 2366 | 0.080 |
Why?
|
Doxorubicin | 3 | 2020 | 2215 | 0.080 |
Why?
|
Survival Rate | 2 | 2019 | 12773 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2021 | 6534 | 0.080 |
Why?
|
Daunorubicin | 2 | 2019 | 149 | 0.080 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18006 | 0.080 |
Why?
|
Aclarubicin | 2 | 2017 | 12 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2536 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1515 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5385 | 0.070 |
Why?
|
Vincristine | 2 | 2020 | 1036 | 0.070 |
Why?
|
Nausea | 2 | 2022 | 665 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6756 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2940 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5655 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2020 | 62966 | 0.070 |
Why?
|
Thrombosis | 1 | 2019 | 2966 | 0.070 |
Why?
|
Pyrimidines | 1 | 2017 | 2933 | 0.070 |
Why?
|
Young Adult | 7 | 2021 | 56350 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5522 | 0.060 |
Why?
|
Adolescent | 8 | 2020 | 85649 | 0.060 |
Why?
|
Etoposide | 2 | 2016 | 637 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3070 | 0.060 |
Why?
|
Prednisone | 2 | 2020 | 1567 | 0.060 |
Why?
|
Fatal Outcome | 2 | 2019 | 1849 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15530 | 0.050 |
Why?
|
Myeloma Proteins | 1 | 2021 | 70 | 0.050 |
Why?
|
Ataxia Telangiectasia | 1 | 2022 | 107 | 0.050 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2022 | 115 | 0.050 |
Why?
|
Rats, Inbred WKY | 1 | 2021 | 158 | 0.050 |
Why?
|
Rats, Inbred SHR | 1 | 2021 | 195 | 0.050 |
Why?
|
Immunoglobulin Light Chains | 1 | 2021 | 276 | 0.050 |
Why?
|
Hypertension | 1 | 2021 | 8455 | 0.050 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.050 |
Why?
|
Neutralization Tests | 1 | 2022 | 758 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7153 | 0.040 |
Why?
|
Body Surface Area | 1 | 2020 | 198 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2020 | 113 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12344 | 0.040 |
Why?
|
Prothrombin Time | 1 | 2019 | 119 | 0.040 |
Why?
|
Idarubicin | 1 | 2019 | 62 | 0.040 |
Why?
|
Benzamidines | 1 | 2018 | 25 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 632 | 0.040 |
Why?
|
Blood Component Transfusion | 1 | 2019 | 142 | 0.040 |
Why?
|
Tryptophan | 1 | 2020 | 478 | 0.040 |
Why?
|
Animals | 5 | 2024 | 168561 | 0.040 |
Why?
|
Bleomycin | 1 | 2019 | 499 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11001 | 0.040 |
Why?
|
Decision Trees | 1 | 2019 | 506 | 0.040 |
Why?
|
Vinblastine | 1 | 2019 | 490 | 0.040 |
Why?
|
Mice | 2 | 2024 | 81045 | 0.040 |
Why?
|
Kidney Tubules | 1 | 2019 | 486 | 0.040 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 179 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2019 | 425 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2017 | 245 | 0.040 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2017 | 300 | 0.040 |
Why?
|
Isoantigens | 1 | 2019 | 567 | 0.040 |
Why?
|
Cytogenetic Analysis | 1 | 2017 | 295 | 0.040 |
Why?
|
Nitrosourea Compounds | 1 | 2016 | 32 | 0.040 |
Why?
|
Primary Myelofibrosis | 1 | 2019 | 214 | 0.040 |
Why?
|
Glycolysis | 1 | 2020 | 825 | 0.040 |
Why?
|
Genes, myc | 1 | 2017 | 399 | 0.030 |
Why?
|
Dacarbazine | 1 | 2019 | 567 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 969 | 0.030 |
Why?
|
Plasma | 1 | 2019 | 575 | 0.030 |
Why?
|
Fibrinogen | 1 | 2019 | 894 | 0.030 |
Why?
|
Mitoxantrone | 1 | 2016 | 149 | 0.030 |
Why?
|
Fatty Acids | 1 | 2024 | 1806 | 0.030 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2017 | 462 | 0.030 |
Why?
|
Pleural Effusion | 1 | 2019 | 338 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2018 | 981 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20086 | 0.030 |
Why?
|
Steroids | 1 | 2020 | 931 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10248 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1006 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 281 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2524 | 0.030 |
Why?
|
Melphalan | 1 | 2016 | 431 | 0.030 |
Why?
|
Japan | 1 | 2018 | 1360 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 604 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 694 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15056 | 0.030 |
Why?
|
Time Factors | 3 | 2021 | 40054 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1679 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2019 | 854 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2020 | 1379 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5163 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1970 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2020 | 2763 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2842 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1866 | 0.030 |
Why?
|
Glucose | 1 | 2024 | 4391 | 0.030 |
Why?
|
Area Under Curve | 1 | 2015 | 1653 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2019 | 2382 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3444 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3164 | 0.020 |
Why?
|
Endoscopy | 1 | 2020 | 1774 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2017 | 2638 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2019 | 1780 | 0.020 |
Why?
|
Kinetics | 1 | 2018 | 6474 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 20928 | 0.020 |
Why?
|
Acute Disease | 1 | 2020 | 7141 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2924 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1771 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2450 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2723 | 0.020 |
Why?
|
Neutrophils | 1 | 2020 | 3711 | 0.020 |
Why?
|
Risk Factors | 3 | 2020 | 72145 | 0.020 |
Why?
|
Hemorrhage | 1 | 2019 | 3461 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5975 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4839 | 0.020 |
Why?
|
Rats | 1 | 2021 | 24265 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10943 | 0.010 |
Why?
|
Anticoagulants | 1 | 2018 | 4595 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9846 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10472 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39004 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29717 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40450 | 0.010 |
Why?
|